Jupiter Neurosciences FY26 Q2 net loss widens 0.95% to $2.27 million; revenue totals $24,245

• Jupiter Neurosciences posted a Q2 net loss of $2.27 million, widening slightly from a year earlier; loss per share improved to $4.08.
• Revenue totaled $24,245, up from no revenue a year earlier; operating loss widened to $2.74 million.
• R&D expense fell 21% to $600,353, while G&A climbed 44% to $2.16 million due to higher payroll and consulting costs.
• Other income rose to $468,548 on a $549,098 gain from marking convertible notes to market; interest expense jumped to $90,618.
• Pharmaceutical pipeline advanced with an FDA-cleared Parkinson’s Phase IIa trial starting in Q2; Nugevia supplement sales began shipping in Q4 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038463), on August 14, 2026, and is solely responsible for the information contained therein.